Quick Read Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share.

Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results,

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion in revenue. Wegovy generated approximately $9 billion -- despite having been approved in the U.S. more than two years before its competitor.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than two months.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue growth in the midst of intense demand for obesity therapies.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that,

Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind Wall Street’s expectations. Shares of rival Novo ...

(Editor’s note: This story was written before Eli Manning was not included in the Pro Football Hall of Fame class of 2025.) Two guys are sitting in a bar. They could be talking about who the Giants’ next quarterback should be, or what went wrong with ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping Wegovy or Zepbound injections.

Eli Grant has a history on Days of Our Lives that goes beyond when the character first appeared as an adult in February 2017. So we’re here to fill in the blanks and answer any questions you might have about his past in Salem. Lamon Archey has been ...